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Protein aggregates are one of the several risk factors for undesired immunogenicity of bio-
pharmaceuticals. However, it remains unclear which features determine whether aggregates will trigger
an unwanted immune response. The aim of this study was to determine the effect of aggregates' size on
their relative immunogenicity. A monoclonal murine IgG1 was stressed by exposure to low pH and
elevated temperature followed by stirring to obtain aggregates widely differing in size. Aggregate frac-
tions enriched in soluble oligomers, submicron size particles and micron size particles were isolated via
centrifugation or size-exclusion chromatography and characterized physicochemically. The secondary
and tertiary structures of aggregates were altered in a similar way for all the fractions, while no sub-
stantial chemical degradation was observed. Development of anti-drug antibodies was measured after
subcutaneous administration of each enriched fraction to BALB/c mice. Among all tested fractions, the
most immunogenic was the one highly enriched in submicron size particles (~100-1000 nm). Fractions
composed of micron size (>1-100 mm) particles or soluble oligomers (<100 nm) were not immunogenic
under the dosing regimen studied in this work. These results show that aggregate size is an important
factor for protein immunogenicity.
© 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.Introduction
Monoclonal antibodies are the most widely used class of ther-
apeutic proteins.1 Reported rates of anti-drug antibodies (ADA)
formation in patients during mAb treatments vary from 0% to
almost 90%.2,3 ADA generation can lead to a decrease in efficacy by
altering the pharmacokinetics and pharmacodynamics, potentially
resulting in severe clinical consequences.2-5 The presence of protein
aggregates in formulated drug is commonly believed to be one of
the crucial risk factors contributing to ADA formation. A number of
in vitro and in vivo studies have confirmed that aggregated proteins
are more immunogenic than monomeric ones.6-11 Moreover, it hassor at Coriolis Pharma, Mar-




®. Published by Elsevier Inc. All rigbeen suggested that aggregates with different features significantly
differ in their ability to trigger ADA.11,12 Unfortunately, in the ma-
jority of studies, unfractionated protein aggregates were tested for
their ability to trigger ADA, so it remains unclear which attributes
contribute to the immunogenicity of protein aggregates.
Size is one of the most commonly used ways in which aggre-
gates are classified. However, data linking aggregate size to
immunogenicity is very limited. Only a few preclinical reports are
available in which immunogenicity of aggregates was studied
in vitro or in vivo with respect to their size.13-16 Moreover, the
results of these studies are somewhat conflicting. In part of them,
micron-sized aggregates were found to be the more immunogenic
than other tested sizes.15,16 Other studies correlated higher
immunogenicity with smaller aggregates, for example, oligomers.14
However, these studies often included only aggregates of a narrow
size range and structurally different aggregates. For example, Bessa
et al.13 showed that oligomers are more immunogenic in mice than
monomers, but they did not study larger aggregates. In another
report, Fathallah et al.14 suggested higher immunogenicity ofhts reserved.
Table 1
Overview of the Samples Prepared and Studied in This Article
Sample Stress Treatment Isolation
“Unstressed” - -
“SEC monomers” pH 4.6, 59C, 30 min SEC
“SEC oligomers” pH 4.6, 59C, 30 min SEC
“SEC oligomers purified” pH 4.6, 59C, 30 min SEC þ centrifugation
(18,000  g, 30 min)
“SEC unfractionated” pH 4.6, 59C, 30 min -
“Supernatant” pH 4.6, 59C, 63 min þ
stirring, 30 min
Centrifugation (3000 x g,
10 min)
“Pellet” pH 4.6, 59C, 63 min þ
stirring, 30 min
Centrifugation (3000 x g,
10 min)
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However, the structure of proteins forming micron size particles
was highly disrupted in contrast to native-like protein molecules
found in oligomers. Several studies have shown that aggregates
composed of fully denatured protein molecules do not elicit anti-
bodies cross-reacting with the native species, in contrast to
aggregates of proteins with considerable native-like structure.17
Another factor blurring the available data is the fact that in cur-
rent literature multiple distinct aggregate size classifications can be
found. Some of them are based on subjective terms, for example,
“subvisible particles” or “soluble oligomers” and not on measurable
features like diameter or volume.18 Therefore, currently there is no
consensus on the role of aggregate size in triggering of ADA.
The aim of our study was to compare the relative immunoge-
nicity of mAb aggregates in awide size range (10 nm-100 mm) upon
subcutaneous (SC) administration in Balb/c mice. We have chosen
this mouse strain because it has been widely used in immunoge-
nicity studies, either directly as “wild type” model, as background
strain for the development of transgenic mouse models, or cross-
bred with other mouse strains to obtain the desired model.15,19-21
To avoid introduction of highly immunogenic foreign epitopes,
which might mask the effect of aggregation on immunogenicity,
recombinant monoclonal murine IgG1 (mIgG1) was used as a
model protein. Such an approach has been previously used to
mimic a patient's immune tolerance status toward recombinant
human therapeutics.17,22 The IgG1 was subjected to stress condi-
tions to generate aggregates of various sizes with similar structural
features. The obtained aggregateswere separated according to their
size by either centrifugation or size-exclusion chromatography
(SEC). Fractions enriched in different sizes of aggregates were then
injected SC into mice, and immunogenicity was determined by
measuring ADA levels in serum. The fraction enriched in submicron
size particles was found to be significantlymore immunogenic than
fractions containing mainly micron size particles or soluble oligo-
mers smaller than 100 nm.
Materials and Methods
Monoclonal Antibody
Recombinant monoclonal mIgG1 (pI: 6.8) targeting an E coli
pilus FimH was provided by MedImmune. The mIgG1 was formu-
lated in histidine buffered saline (25 mM histidine, 150 mM NaCl,
pH 6.0). Before stress treatment, the mIgG1 was buffer-exchanged
into phosphate buffered saline (PBS, 1.54 mM KH2PO4, 2.7 mM
Na2HPO4-7 H2O, 155 mM NaCl, pH 7.2) obtained from Life Tech-
nologies (Paisley, UK). PD-10 columns (GE Healthcare,
Buckinghamshire, UK) were used according to the manufacturer's
protocol to replace the formulation buffer.
Generation and Fractionation of Aggregates
Aggregation was generated according to the protocol devel-
oped for a fluorescently labeled version of the same mIgG1 and
described by Kijanka et al.23 However, as unconjugated mIgG1
displayed a slightly better stability than labeled mIgG1, a higher
temperature (59C instead of 55C) and a longer incubation time
(63 min vs. 60 min) were used to generate aggregates (see Table 1
for overview of the prepared solutions). In brief, for
centrifugation-based fractionation, the mIgG1 was diluted in PBS
to a final concentration of 2 mg/mL. Next, 500 mL of mIgG1 solu-
tion was mixed with an equal volume of “low pH buffer” (0.1 M
Na2HPO4, 0.05 M citric acid, pH 4.6). The obtained solution was
first incubated at 59C for 63 min, followed by 30 min of stirring
(700 rpm) at room temperature. After neutralization with 1 MNaOH, the solution was centrifuged (3000  g, 10 min, 4C).
“Supernatant,” the fraction enriched in submicron size particles,
was transferred into a new tube. “Pellet,” the fraction enriched in
micron size particles, was suspended in fresh PBS by pipetting
“up-and-down” 10 times.
For SEC-based fractionation, 500 mL of mIgG1 (14 mg/mL in PBS)
was mixed with an equal volume of “low pH buffer.” Next, the so-
lution was incubated at 59C for 30 min. The sample was cooled
down at 4C for 10 min and neutralized with 1 M NaOH. This
stressed, unfractionated sample is referred to as “SEC Unfractio-
nated.” The resulting solution was filtered through a 0.22 mm filter
(Millipore, Carrigtwohill, Ireland) and fractions were isolated via
SEC on an Agilent 1200 system (Agilent Technologies, Palo Alto, CA)
equipped with an autoinjector and fraction collector. Fractions
were separated on a High Load Superdex 200 PG column (GE
Healthcare). A volume of 0.9 mL of aggregated protein solution was
injected onto the column, PBS was used as mobile phase, and the
flow rate was 1 mL/min. The fraction collected between 45-50 min
of separation, referred to as “SEC Oligomers,” was enriched in
oligomers and submicron size particles (see Supplementary
Fig. S1). Next, 2.5 mL of “SEC Oligomers” fraction was further pu-
rified by filtration through a 0.1-mm polyvinylidene fluoride filter
(Millipore) followed by centrifugation (18,000  g, 30 min, 4C).
The supernatant thus obtained, referred to as “SEC Oligomers Pu-
rified,” was transferred into a new tube. The monomers subjected
to stress conditions were collected between 65-70 min of separa-
tion and are referred to as “SEC monomers.” All samples were
prepared freshly at the day of administration and were stored for
up to 4 h at 4C prior to injection.
The total protein concentration of all aggregated species in the
obtained fractions was determined by microBCA assay (Thermo
Fisher Scientific, Rockford, IL) according to the supplier's protocol.
Samples were screened for endotoxin contamination with the
Pierce® LAL Chromogenic Endotoxin Quantitation Kit according to
the manufacturer's protocol (Thermo Fisher Scientific). For all
tested fractions, except “GPC Monomer,” the measured endotoxin
level was below the detection limit of the assay, that is, <0.1
endotoxin unit (EU) per mL of the injected solution or <0.02 EU/
injected dose. The endotoxin levels in “GPC Monomer” were at
maximum 0.5 UE/mL, corresponding to 0.1 EU/injected dose. As an
adult Balb/c mouse weighs about 25 g, the maximum
administered dose of endotoxins in “GPCMonomer”was 4 EU/kg/h,
which is below the United States Pharmacopeia <85 > chapter's
limit for injectable solutions of 5 EU/kg/h24
Characterization of Aggregates
High-Performance SEC
High-performance (HP-SEC) was used to quantify the content of
monomers and oligomers in isolated fractions. Samples were
analyzed on an Agilent 1200 system (Agilent Technologies)
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multiangle laser light scattering (MALLS) Dawn Helios detector
(Wyatt Technology, Dernbach, Germany). Before analysis, all sam-
ples were centrifuged (10,000 g, 10 min, 4C). Fifty micrograms of
each fraction were analyzed on a TSK Gel 4000 SWXL column
(Tosoh Bioscience, King of Prussia, PA). PBS supplemented with 0.2
M arginine was used as the mobile phase and the flow rate was 1
mL/min. The protein peaks were detected at 280 nm, and the mo-
lecular weight of the eluting material was calculated on the basis of
MALLS data in Astra V 5.3.4.20 software (Wyatt Technology).
Dynamic Light Scattering
Samples were analyzed with a Malvern Zetasizer Nano ZS
(Malvern, Herrenberg, Germany) equipped with a 633 nm He-Ne
laser operating at an angle of 173. Data were collected with the
Zetasizer Software v.7.11 (Malvern). A 500 mL of each fraction was
measured in a polystyrene semi-micro cuvette (Brand, Wertheim,
Germany) with a 10 mm path length. The measurements were
performed at 25C with an automatic attenuation, run duration,
and number of runs. The mean Z-average (Zave) diameter and
polydispersity index (PDI) are reported.
Nanoparticle Track Analysis
Nanoparticle track analysis (NTA) was used to determine the
number of submicron size particles (size range 0.1-1 mm) in the
samples. The measurements were performed with a NanoSight
LM20 (NanoSight, Amesbury, UK), equipped with a sample cham-
ber with a 640 nm laser and a syringe pump. The samples were
measured for 90 s with manual adjustment of shutter and gain.
Each sample was measured 3 times. The “Unstressed,” “SEC
monomers,” “SEC oligomers,” “SEC Oligomers Purified,” “SEC
Unfractionated,” and “Pellet” fractions were diluted 10-fold with
PBS prior to analysis, whereas “Supernatant” needed to be diluted
100-fold because of the very high particle load. The data were ac-
quired and analyzed by the NTA 2.3 software (NanoSight).
Micro-Flow Imaging
The number of micron size aggregates (size range 1-100 mm)
was determined by an micro-flow imaging (MFI) DPA4100 series A
system (ProteinSimple, Santa Clara, CA) equipped with a silane
coated 100 mm flow cell (ProteinSimple) and operated at high
magnification (14). Samples of 0.55 mL with a prerun volume of
0.2 mL were analyzed at a flow rate of 0.17 mL/min (n ¼ 3). The
“Unstressed,” “SEC monomers,” “SEC oligomers,” “SEC Oligomers
Purified,” and “Supernatant” fractions were diluted 10-fold with
PBS prior to analysis. For analysis of “Pellet” and “SEC unfractio-
nated” samples, a 100-fold dilution was necessary. Data were ac-
quired by MFI View software, version 6.9 and analyzed with MVAS,
version 1.2 (ProteinSimple).
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
One microgram of protein from each fraction was separated on
4%-15%Mini-Protean® TGX™ precast gel (Bio-Rad Laboratories B.V.,
Veenendaal, The Netherlands). A Laemmli sample buffer (Bio-Rad
Laboratories B.V.) was used for samples analyzed under nonre-
ducing conditions. To obtain reducing conditions, b-mercaptoe-
thanol (Bio-Rad Laboratories B.V.) was added to Laemmli buffer to a
final concentration of 355 mM. Prior to loading on the gel, samples
were boiled at 95C for 5 min. The electrophoresis was performed
with a Biorad Mini-Protean module and 25 mM Tris, 192 mM
glycine, 0.1% SDS, pH 8.3 (Bio-Rad Laboratories B.V.) as a running
buffer. Separation was initiated with electrophoresis at 80 V for
10 min, followed by 120 V for 50 min. Spectra™ Multicolor High
Range Protein Ladder (Thermo Fisher Scientific) and Precision Plus
Protein™ All Blue Standards (Bio-Rad Laboratories B.V.) wereincluded for molecular weight determination. Silver Stain Plus kit
(Bio-Rad Laboratories B.V.) was used for visualization of the protein
bands. The images of gels were acquired with a GS-900 densi-
tometer (Bio-Rad Laboratories B.V.) and Image Lab v.5.2.1 software
(Bio-Rad Laboratories B.V.).
Western Blotting and Dot Blotting
For Western blot analysis, 0.1 mg protein of each fraction was
separated by SDS-PAGE under nonreducing conditions as previ-
ously described. SDS-PAGE gels were blotted onto a supported
nitrocellulose sheet (Bio-Rad Laboratories B.V.) with a Biorad Mini
Trans-Blot electrophoretic transfer cell. Running buffer was
composed of 25 mM Tris, 192 mM glycine, and 20% methanol, pH
8.3. After blotting, the membranes were blocked overnight at 4C
with 2% bovine serum albumin (BSA) in PBS supplemented with
0.05% Tween 20 (PBST). Next, the blots were incubated for 1 h at
ambient temperaturewith peroxidase labeled anti-mouse total IgG,
IgG1, IgG2a (Southern Biotech, Birmingham, AL), all diluted 2000-
fold in PBST. Then, the membranes were washed 3 times with
PBST followed by 2 PBS washes and developed with AEC chromo-
genic substrate (Sigma-Aldrich Chemie B.V., Zwijndrecht, The
Netherlands) according to the manufacturer's protocol.
In addition to blots developed with commercially available
detecting mAb, mIgG1 aggregates were visualized with specific
anti-mIgG1 polyclonal antibody purified from sera of rabbits
immunized with mIgG1 by Covance (Denver, PA). After blocking,
the membrane was incubated for 1 h at ambient temperature with
rabbit anti-mIgG1 diluted 2000-fold in PBST. Next blot was first
washed 3 times with PBST and then incubated for another 1 h with
peroxidase-labeled anti-rabbit Ab (Thermo Fisher Scientific),
diluted 2000-fold in PBST. Finally, the membrane was washed and
developed with AEC chromogenic substrate as previously
described.
Dot blots were prepared by applying of 0.1 mg of each fraction on
a nitrocellulose membrane. After air drying of the samples, blots
were blocked and developed according to protocols used for
Western blots.
Far-UV Circular Dichroism Spectroscopy
For far-UV circular dichroism (CD), the mIgG1 fractions were
diluted in PBS to 0.1 mg/mL. The CD spectra were measured with a
Jasco J-815 CD spectrometer (Jasco International, Tokyo, Japan) in a
quartz cuvette with a path length of 0.2 cm at 25C. The CD spectra
were collected from 200 to 260 nm at a speed of 20 nm/min, a data
pitch of 0.5 nm, a response time of 8 s, and a bandwidth of 1 nm.
Five accumulations were collected for each sample. Spectra were
smoothed with GraphPad Prism®, v 5.02 (GraphPad Software, Inc.,
La Jolla) by using 0th order polynomial smoothing and 4 neighbors
on each value as described previously.25 Next, spectra were back-
ground corrected for the baseline spectrum of PBS. A mean residue
ellipticity ([q] mean residue weight [MRW]) was calculated
according to Kelly et al.,26 using an MRWof 112.35 (MRW ¼M/N-1,
where M is the molecular mass, i.e., 148,300 Da, and N is number of
amino acids residues of mIgG1, [i.e., 1320]).
Fluorescence Spectroscopy
The fluorescence emission spectra of isolated fractions were
measured with a steady state fluorimeter FS900 (Edinburgh In-
struments Ltd., Livingston, UK). All measurements were performed
in a quartz cuvette of 1 cm path length and 1 mL of 0.1 mg/mL
sample was used. The intrinsic fluorescence of tryptophan residues
was recorded from 310 to 400 nm on excitation at 295 nm using
slits of 3 nm, a dwell time of 1 s, steps of 0.5 nm, and a cumulative
addition of 3 scans for each spectrum. All spectra were first
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for the spectrum of the PBS.
Next, 4,4'-dianilino-1,1'-binaphthyl-5,50-disulfonic acid dipo-
tassium salt (Bis-ANS; Sigma-Aldrich B.V.) was added to each
fraction to a final concentration of 1 mM. The Bis-ANS was excited at
385 nm, and the fluorescence emission was recorded from 410 nm
to 600 nmwith 1 nm steps and a dwell time of 1 s. Both excitation
and emission slits were set to 5 nm, and a cumulative addition of 3
scans for each spectrum was collected. Obtained spectra were
smoothed and buffer corrected as previously described.
Tryptic Peptide Mapping Using Liquid Chromatography Coupled
With Mass Spectrometry
Assessment of potential posttranslational modifications (PTMs)
and stress-induced chemical degradation was performed by tryptic
digest peptide mapping of unstressed mIgG and unfractionated
aggregated mIgG samples. Denaturation and reduction of 100 mg
protein (100 mL protein samples at 1 mg/mL) was performed by
addition of 200 mL of 8 M guanidine, 130 mM Tris, 1 mM EDTA, pH
7.6, and 10 mL of 500 mM DTT (Thermo Fisher Scientific, Waltham,
MA), followed by incubation for 30 min at 37C. Samples were
alkylated with the addition of 25 mL of 500 mM iodoacetamide (G-
Biosciences, St. Louis, MO) followed by a 30 min incubation while
protected from light at ambient temperature. Samples were buffer-
exchanged into 2 M urea, 100 mM Tris, pH 7.6 by centrifugal
filtration with a 10 kDa MW membrane (Millipore Sigma, St. Louis,
MO). Samples were digested at 37C for 4 h by using 5 mg trypsin,
then quenched with 4% trifluoroacetic acid and collected for
analysis.
The digested peptides were separated on aWaters Acquity UPLC
system with autosampler and tunable ultraviolet detector (Waters
Corporation, Milford, MA) equipped with a BEH300 C18 column
(1.7 mm, 2.1  150 mm) (Waters Corporation) using a gradient
elution from 100% to 65% mobile phase A (0.02% TFA in water,
mobile phase B was 0.02% TFA/acetonitrile) at a flow rate of 0.2 mL/
min (total elution time of 78 min). Eluted peptides were detected
by UV absorbance at 220 nm and analyzed by a Waters Synapt G2
QTOFmass spectrometer (Waters Corporation). Datawere analyzed
using Waters UNIFI and MassLynx software (Waters Corporation).
Estimation of Protein Mass Within Different Size Ranges of
Aggregates
HP-SEC, NTA, andMFI were used to calculate the mass of protein
in different size ranges for each enriched fraction. The total
estimate of protein mass in the different size ranges for each of the
injected fractions was compared to the experimental microBCA
assay value for total protein mass in the fractions to assess the
accuracy of the calculated compositions. The mass of mIgG1 frag-
ments, monomers, and oligomers was calculated from the peak
areas under the curve (AUC) in the HP-SEC analysis. The “Un-
stressed” controls were used as references for recovery calcula-
tions. The AUC of unstressed mIgG1 (100%) corresponded to the
mass of analyzed protein, that is, 50 mg. The recovery of stressed
fractions was calculated by comparing their AUC to that of the
corresponding “Unstressed” mIgG1.
The mass of protein in submicron size particles and micron size
particles was calculated on the basis of NTA and MFI data as
described previously.23,27,28 In short, mass was assessed according
to the formula proposed by Barnard et al.:27 M ¼ d*V*n*p, where
d is the density of the protein (1.4 mg/mL), V is the volume of
particles per size bin (width: 1 nm for NTA and 0.25 mm MFI), n is
the number of particles per size bin, and p is the fraction of the
particle volume (V) occupied by protein (assumed to be 0.75). The
mass of all submicron size particles was obtained by summing up
the masses of the particles in all size bins determined by NTA. Thesame strategy was used to estimate the mass of micron size par-
ticles determined by MFI. The calculated mass composition of
fractions is expressed as percentage of total protein per mL
measured with microBCA assay.
Animal Study
Mice
BALB/c mice of 6-8 weeks age were obtained from Charles River
Laboratory (L'Arbreske Cedex, France) and kept in standard cages
with access to food and water (acidified) ad libitum. All testing was
conducted with approval of the Animal Ethic Committee of Leiden
University Medical Center (permission number 14096).
Animal Experiments
In the first experiment, referred to as experiment I, a total
number of 84 mice was divided into 7 groups (n ¼ 12) of which 6
were treated with different stressed fractions and one with un-
stressed mIgG1 as a control. Mice were injected SC between the
shoulders twice per week for 8 weeks with 10 mg of protein per
injection diluted in endotoxin free PBS. BD Micro-FineTM 0.5 mL
insulin syringes with a permanently attached 31G needle (Becton
Dickinson B.V., Breda, The Netherlands) were used for the
injections. The basal level of ADAwas determined for eachmouse in
blood collected submandibularly prior to the first injection. From
each mouse, blood was collected every second week. Mice were
sacrificed 2 weeks after the last injection (day 65). The adminis-
tration regimen is schematically shown in Figure 1. This study
design, consisting of 16 injections of 10 mg of protein per injection
over an 8-week time period, has been chosen based on pilot studies
and was found to be the most discriminative among the tested
regimes.
In the follow-up experiment, referred to as experiment II, mice
(n ¼ 16 per group) were administered with 3, 10, and 30 mg of
“Supernatant” fraction per injection to determine the impact of
aggregates' dose on the immunogenicity. Unstressed mIgG1 was
used as a control (n ¼ 16). Administration route and duration,
injection frequency, and blood collection regimen described pre-
viously were used. One week after the first 2 injections (day 10), 4
mice from each group were euthanized, and spleens as well as
draining lymph nodes (LNs), that is, brachial and axillary LNs, were
extracted. The remaining mice were sacrificed on day 65.
Blood was collected into the MiniCollect® Serum Z separator
tubes (Greiner Bio-One, Alphen aan den Rijn, The Netherlands).
Serum was isolated by centrifugation (3000  g, 10 min), collected
into storage tubes (Thermo Fisher Scientific) and kept at 80C for
analysis.
Anti-drug Antibody Detection
The ADA screening was performed with a bridging ELISA ac-
cording to an adopted protocol previously described by Qiu et al.29
The capture and detection reagents, mIgG1-biotin and mIgG1-
digoxigenin, were obtained by labeling of mIgG1 with EZ-Link®
sulfo-NHS-LC-biotin (Thermo Fisher Scientific) or 3-amino-3-
deoxydigoxigenin hemisuccinamide, succinimidyl ester (Thermo
Fisher Scientific) according to the manufacturer's protocols. Dul-
becco's PBS (Life Technologies) supplemented with 0.5% BSA
(Sigma-Aldrich Chemie B.V) was used as the assay buffer. The
polyclonal rabbit anti-mIgG1 antibody used as the positive control
in ADA assay was generated and purified by Covance. Samples and
polyclonal ADA controls (spiked in pooled BALB/c sera) were
diluted at a minimum dilution of 1/100 in assay buffer and incu-
bated overnight with mIgG1-biotin and mIgG1-digoxigenin
(1.25 mg/mL each), during which a portion of ADA present in the
sample bound to both conjugated forms of mIgG1 at the same time.
Figure 1. Graphical representation of the administration regimen, blood collection frequency, and experimental end points at which mice were euthanized. ADA detection was
performed on blood samples collected at every blood collection time point and during euthanasia. In addition, in experiment II, spleens and draining LNs were collected during
euthanasia for the detection of follicular TFH cells.
G. Kijanka et al. / Journal of Pharmaceutical Sciences 107 (2018) 2847-2859 2851On the following day, samples were transferred on a streptavidin-
coated plate (Thermo Fisher Scientific) and incubated at room
temperature for 1 h to capture the ADA-bridged complexes. The
plate was washed 8 times with PBST to remove unbound materials.
Next peroxidase labeled anti-digoxigenin antibody (Jackson
Immunolabs, Suffolk, UK) was added onto a plate to detect bound
ADA. The QuantaRed™ Enhanced Chemifluorescent was used as
the HRP Substrate Kit (Thermo Fisher Scientific). The fluorescence
was exited at 570 nm, and emission at 585 nmwasmeasuredwith a
Tecan Infinity plate reader (Tecan Group Ltd. M€annedorf,
Switzerland). The signal intensity was proportional to the amount
of ADA present in the sample.
The signal of each sample was normalized against background
signal for pooled negative BALB/c sera (Bioreclamation, Westbury).
Serum was classified as positive if the signal-to-background (S/B)
ratio was equal or higher than the cutoff point, defined as the upper
95th percentile of the signal from basal serum samples (n ¼ 84 and
n¼ 64 for experiment I and II, respectively). All samples found to be
positive in the screening assay were tested in a confirmatory assay
in which the unlabeled mIgG1 was used as a competitor during the
overnight incubation step (see the Supplementary Fig. S2 for
further details).Isotyping
The ADA isotypes in positive sera collected in experiment I at the
end of the in vivo experiment were measured with a direct ELISA.
First, Maxisorp 96-well plates (Thermo Fisher Scientific) were
coated overnight with 1 mg/mL mIgG1 in PBS at 4C. Next, plates
were washed 8 times with PBST and blocked for 1 h with 4% nonfat
milk (Campina, Zaltbommel, Netherlands) in PBST (PBST/M). After
another washing step, sera (100  diluted in PBST/M) were added
into the wells, and the plates were incubated for 1 h at RT with
constant orbital shaking. ADA was detected with peroxidase-
labeled anti-mouse IgM, IgG2a, IgG2b, and IgG3 Abs diluted
1:2000 in PBST/M (Life Technologies, Rockford). The IgG1 subclass
was not measured due to interference of plate coating material
(mIgG1) with detection reagents (anti-mouse IgG1 Abs). Next, the
plates were washed again and developed with QuantaRed
substrate. After incubation for 15 min, the reaction was stopped,
and 100 mL of reaction solutions were transferred into the wells of
black 96-well plates. The fluorescence was excited at 570 nm and
emission at 585 nm was measured with a Tecan Infinity plate
reader. The signal of each sample was normalized against back-
ground signal for negative BALB/c sera.Follicular T Helper (TFH) Cell Detection
Single cell solution was prepared by pressing spleens and LNs
isolated during experiment II through a Falcon® 70 mm cell strainer
(Corning, Amsterdam, The Netherlands). Next, red blood cellspresent in splenocytes solution were lysed with ACK lysis buffer
(Thermo Fisher Scientific) according to manufacturer's protocol.
Approximately, 100,000 cells were suspended in cold 100 mL of PBS
with 1% BSA (PBSB) and stained with anti-CD3-FITC, CD4-e-
Fluor450, CXCR5-PeCy7 and PD1-PE Abs (all eBioscences, Vienna,
Austria) diluted according to manufacturer's protocol. After 40 min
incubation, cells were spun down (10min at 350 g), and unbound
detecting reagents were removed by 2 times washing with PBSB.
After the last wash step, cells were fixed with 1% polyformaldehyde
in PBS and analyzed with FACS Canto II flow cytometer (BD Bio-
sciences, Vianen, The Netherlands). Obtained data were analyzed
with FlowJo® X (FlowJo LLC, Ashland). The gating strategy used to
detect TFH cells is shown in Supplementary Figure S3.Statistical Analysis
The potential difference between ADA responses upon injection
of different fractions was assessed with 1-way ANOVA with the
Tukey's multiple comparison test. Calculations were performed in
GraphPad Prism® v.5.02 software.Results
Detection and Quantification of Aggregates
All fractions tested in in vivo experiments were analyzed by
using 4 complementary techniques covering a size range from
fragments to particles of 100 mm in diameter, that is, dynamic light
scattering (DLS), HP-SEC, NTA, and MFI (Fig. 2 and Tables 2 and 3).
The collective datawere used to quantitatively estimate themass of
protein in the form of fragments, monomers, dimers, oligomers
(MW  17$MDa, according to MALLS, see Supplementary Fig. S1),
submicron particles (0.1-1 mm) and micron particles (1-100 mm) for
the different fractions. The results are summarized in Figure 3. One
has to keep in mind that this estimation includes errors due to
instrument limitations (e.g., gap or overlap in measured size ranges
of used techniques) and assumptions used in the calculations (i.e.,
spherical aggregates, protein density of 1.4 g/mL, particle porosity
of 25%, and lack of interactions with HP-SEC column material).
These limitations are probable causes of apparent recoveries that
were incomplete (e.g., “SEC oligomers purified”) or exceeded 100%
(e.g., “Supernatant” and “Pellet”) when compared to the actual
experimental total mass by microBCA.
The HP-SEC analysis of “Unstressed” and “SEC monomers”
(Fig. 2a) confirmed that those fractions were mainly composed of
monomeric mIgG1 (97% and 99%, respectively). Both fractions
contained, besides monomers, a low percentage of dimers (1.7% vs.
1.5%, respectively, in “Unstressed” and “SEC monomers”) and olig-
omers (0.8% vs. 1.1%, respectively). However, “SEC monomers” had
higher estimated amounts of submicron size aggregates than
Figure 2. Size distribution of mIgG1 fractions. (a) Representative HP-SEC chromatogram recorded at 280 nm, (b) average submicron particles size distribution of all injected so-
lutions (n ¼ 16) measured with NTA and (c) average ± SD micron size particles size distribution of all injected solutions (n ¼ 16), measured with MFI.
G. Kijanka et al. / Journal of Pharmaceutical Sciences 107 (2018) 2847-28592852“Unstressed” (4% vs. 0.5%, respectively, Fig. 2b). Both of those
fractions had a very low content of micron size aggregates (0.03% in
“Unstressed” sample and 0.3% in “SEC monomers,” Fig. 2c). The
measured Zave of “Unstressed” mIgG1 was 12 ± 1 nm (PDI 0.11 ±
0.06), which corresponds with the expected size of monomeric
antibody. In contrast, the Zave of “SEC monomers”was 121 ± 72 nm
(PDI 0.25 ± 0.05), most likely due to presence of submicron parti-
cles in this fraction.
As expected, the “Supernatant” fraction was found to contain
the highest number of submicron size particles among all fractions
(Fig. 2b). The Zave of particles in “Supernatant”was 179 ± 20 nm and
the PDI was 0.21 ± 0.01, suggesting a relatively narrow particle size
distribution in this fraction. The amount of mIgG1 in submicron
particles was estimated to be 135%, which must be an over-
estimation, also because a substantial amount of oligomers (39%)
was observed (Fig. 2a). According to MALLS analysis, aggregatesTable 2
Summary of the Results of DLS Measurements of mIgG1 Fractions Obtained for 3
Representative Batches (Average Values ± SDs)
Sample DLS
Zave [nm] PDI
“Unstressed” 12 ± 1 0.11 ± 0.06
“SEC monomers” 121 ± 72 0.25 ± 0.05
“SEC oligomers” 97 ± 9 0.22 ± 0.02
“SEC oligomers Purified” 73 ± 4 0.16 ± 0.01
“SEC unfractionated” 103 ± 16 0.30 ± 0.09
“Supernatant” 179 ± 20 0.21 ± 0.01
“Pellet” 1867 ± 504 0.80 ± 0.14assigned as soluble oligomers consisted of up to circa 100 mIgG1
monomers (data not shown). The estimated content of residual
micron size particles found in “Supernatant” was 1.8% (Fig. 2c).
Monomeric and dimeric mIgG1 represented 12% and 2.5%,
respectively (Fig. 2a).
The “Pellet” fraction was successfully enriched in micron size
aggregates corresponding to about 100% of protein (Fig. 2c). The
Zave was determined to be 1867 ± 504 nm (PDI 0.80 ± 0.14). More
than 99% of all micron size particles measured with MFI in this
fraction had a size below 10 mm. The submicron size aggregates
accounted for 57% of total protein (Fig. 2b). This fraction contained
hardly any monomers or dimers (both below 0.5% according to HP-
SEC, Fig. 2a). Similar to the “Supernatant” fraction, the “Pellet”
fraction showed a recovery >100%, indicating an overestimation ofTable 3
Number of Submicron and Micron Size Particles in All mIgG1 Fractions Measured by
NTA and MFI, Respectively
Sample Total Particle Concentration
NTA [109/mL] MFI [106/mL]
“Unstressed” 0.1 ± 0.7 0.01 ± 0.01
“SEC monomers” 1.67 ± 1.0 0.12 ± 0.10
“SEC oligomers” 25.9 ± 17.3 0.23 ± 0.22
“SEC oligomers purified” 2.4 ± 2.5 0.08 ± 0.09
“SEC unfractionated” 6.7 ± 4.7 34.1 ± 14.5
“Supernatant” 78.6 ± 30.7 0.34 ± 0.15
“Pellet” 21.1 ± 6.3 81.1 ± 27.4
The average number and SD was calculated for all batches of fractions injected into
mice (n ¼ 16).
Figure 3. Calculated average mass of mIgG1 species in all batches of injected fractions (n ¼ 16) expressed as % of injected dose (% ID, where 100% equals 10 mg as measured by
microBCA).
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particle fractions.
The “SEC Oligomers” and “SEC Oligomers purified” fractions
were composed of low amounts of monomers (4.6% and 4.9%,
respectively, Fig. 2a). Oligomeric IgG1 was the most abundant
protein species in “SEC oligomers” and “SEC Oligomers purified”
(75% and 84%, respectively, Fig. 2a). Dimeric mIgG1 represented
2.3% of these fractions (Fig. 2a). In addition, the unpurified “SEC
Oligomers” contained submicron and micron size particles (34%
and 3.8%, respectively, Figs. 2b and 2c) and the measured Zave was
97 ± 9 nm (PDI 0.22 ± 0.02). These particulates were successfully
removed by filtration and centrifugation, yielding the “SEC Oligo-
mers purified” fraction. The resulting fraction showed a >10-fold
reduction in the estimated amount of submicron size particles
(2.8%, Fig. 2b) and micron size particles (0.3%, Fig. 2c). Upon puri-
fication, the Zave decreased to 73 ± 4 nm (PDI 0.16 ± 0.01).
The “SEC Unfractionated” sample was estimated to contain 20%
of monomers, 4% of dimers, 58% of oligomers (all Fig. 2a), 16% of
submicron size aggregates (Fig. 2b), and 6% of micron size aggre-
gates (Fig. 2c). The Zave was determined to be 103 ± 16 nm (PDI 0.30
± 0.09). The number of micron size aggregates was comparable to
that of “Pellet” (see Table 3); however, they accounted for only
about 6% of total protein. This difference in estimated mass can be
ascribed to the 10-fold lower number of aggregates larger than 10
mm in “SEC Unfractionated” than in “Pellet.”Structural Characterization of Protein in Unstressed and Stressed
Samples
SDS-PAGE
SDS-PAGE analysis under nonreducing conditions showed
mainly monomeric mIgG1 for all the fractions (Fig. 4a), indicating
that most of the aggregates created during stress treatment were
noncovalent. The sample results were impacted by glycosylation asexpected in terms of band broadening and migration that was
slightly retarded compared to the reference ladder. In all fractions
enriched in aggregates, additional bands of covalent aggregates
were found (Fig. 4a). These were most likely composed of dimers
and trimers. However, as these bands appeared above the marker
upper limit, their apparent weight could not be accurately deter-
mined. Addition of b-mercaptoethanol to the sample buffer resul-
ted in reduction of disulfide bridges and complete dissociation of
monomers and aggregates into light and heavy chains (Fig. 4b).
Western Blotting and Dot Blotting
As depicted in Figure 5, aggregation did not affect recognition of
the mIgG1 by anti-mouse total IgG, anti-mouse IgG1, or mIgG1
specific rabbit antibody. This suggests that epitopes present on the
monomeric, unstressed mIgG1 were not destroyed by the aggre-
gation protocol. Moreover, it indicates that the aggregatedmIgG1 in
principle should be capable of inducing antibodies that are cross-
reactive with monomeric mIgG1 and therefore should be detect-
able by our ELISA.
CD Spectroscopy
The influence of aggregation on mIgG1's secondary structure
was assessed with far-UV CD spectroscopy (Fig. 6a). The spectra of
“Unstressed” and “SEC monomers” showed only minor differences,
both being a typical mAb spectrum with b-sheet being predomi-
nant in mIgG1's secondary structure.30,31 Fractions enriched in
oligomers and submicron aggregates, that is, “Supernatant,” “SEC
Oligomers,” and “SEC Oligomers Purified” showed significant
changes in the spectra when compared with “Unstressed.” In all
those samples, a circa 2-fold decrease of the negative molar ellip-
ticity at 218 nm was observed. According to Vermeer et al.31 this
indicates loss of b-sheet and increase in random coil structure, and
it has been reported for other mAbs upon thermal stress treat-
ment.30 Because of interference of light scattering by particles, no
Figure 4. SDS-PAGE analysis of mIgG1 fractions. Samples were analyzed under (a) nonreducing conditions and (b) reducing conditions.
Figure 5. Western blot analysis of the mIgG1 fractions, as detected with anti-mouse total IgG (a), rabbit anti-mIgG1 (b), and anti-mouse IgG1 antibody (c). (d) Dot blot analysis of
mIgG1 fractions. The samples are shown in following order: (1) unstressed, (2) SEC monomers, (3) SEC oligomers, (4) SEC oligomers purified, (5) SEC unfractionated, (6) supernatant,
(7) pellet, (C1) human mAb, and (C2) bovine serum albumin.
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Figure 6. Secondary and tertiary structure analysis of mIgG1 fractions. (a) Far-UV CD spectra, (b) intrinsic tryptophan fluorescence spectra, and (c) fluorescence spectra of Bis-ANS
added to the fractions.
G. Kijanka et al. / Journal of Pharmaceutical Sciences 107 (2018) 2847-2859 2855meaningful CD spectrum could be recorded for the “SEC Unfrac-
tionated” and “Pellet” fractions.Fluorescence Spectroscopy
The occurrence of potential changes in the tertiary structure of
mIgG1 was assessed by measurement of the fluorescence of tryp-
tophan residues. As shown in Figure 6b, no shift in fluorescence
emission maximum in “SEC monomers” was detected when
compared to “Unstressed” control. Both fractions showed a
maximum fluorescence intensity at 344.5 nm. The fractions
enriched in aggregates displayed a small red shift in fluorescence
emission maximum, ranging from 0.5 nm (“SEC Oligomers”) to 2
nm (“Supernatant” and “SEC Oligomers purified”). The intensity of
tryptophan fluorescence in fractions obtained with centrifugation,
that is, “Supernatant” and “Pellet,” was similar to that of “Un-
stressed” control. However, all fractions isolated via SEC, that is,
“SEC monomers,” “SEC Oligomers,” “SEC Oligomers Purified,” as
well as “SEC Unfractionated” showed a lower fluorescence than
that of “Unstressed” mIgG1. This lower fluorescence intensity and
red shift in fluorescence maximum suggest a slightly higher degree
of conformational changes for mIgG1 fractions obtained by SEC
isolation than for fractions obtained by centrifugation.32
In addition to intrinsic fluorescence of mIgG1, fluorescence of
Bis-ANS, an extrinsic probe, was used to detect potential changes in
tertiary structure. The fluorescence intensity of Bis-ANS signifi-
cantly increases in a hydrophobic environment. As shown in
Figure 6c, the intensity of Bis-ANS fluorescence was similarly low in
fractions containing monomeric mIgG1, that is, “Unstressed” and
“SEC monomers.” In contrast, the Bis-ANS fluorescence intensity
increased significantly in the presence of all fractions enriched inaggregates. The fluorescence of Bis-ANS in the presence of “Su-
pernatant” or “Pellet” fractions was higher than in presence of the
“SEC Oligomers,” “SEC Oligomers Purified,” or “SEC Unfractionated”
fractions, indicating higher exposure of hydrophobic patches in
fractions obtained by centrifugation.
Liquid Chromatography Coupled With Mass Spectrometry
Tryptic peptide mapping by liquid chromatography coupled
with mass spectrometry analysis revealed that stress conditions
applied in order to induce aggregation did not result in major
chemical modifications. “Unstressed”mIgG1 contained some PTMs,
that is, low levels of oxidized and deamidated amino acid residues
in the heavy chain (Table 4). The levels of these PTMs were similar
or only slightly increased for the stressed samples (Table 4).
Importantly, no new modifications were detected in any of the
aggregate enriched fractions.
Immunogenicity of Aggregates
In experiment I, the immunogenicity in mice of all tested frac-
tions was studied. As shown in Figure 7a, the tested fractions
yielded significantly different ADA responses (p <0.0001). Themost
immunogenic fraction was the “Supernatant,” that is, the submi-
cron particle-enriched fraction: 58% of the mice (7 out of 12)
treated with this fraction developed measurable levels of ADA after
8 weeks of treatment. The “SEC Oligomers” fraction induced ADA in
16% of the mice (2 out of 12). Only 1 of 12 mice treated with the
“Pellet,” “SEC oligomers Purified,” and “Unfractionated” fractions
showed an ADA response. Interestingly, the ADA was first detected
after 4 weeks (8 injections) of treatment (see Supplementary
Table 4
Results of Peptide Mapping With Liquid Chromatography Coupled With Mass Spectrometry Analysis of the mIgG1 Fractions
Sample % Peak Area
Oxidation
Heavy Chain Light Chain
M34, W36 W47 W110 M255 W37 M49
“Unstressed” 0.9 ND ND 1.1 ND ND
“SEC monomers” 1.1 ND ND 1 ND ND
“SEC oligomers” 2.0 ND ND 2.8 ND ND
“SEC oligomers Purified” 2.1 ND ND 3.0 ND ND
“SEC unfractionated” 1.2 ND ND 1.2 ND ND
“Supernatant” ND ND ND 1 ND ND
“Pellet” 0.8 ND ND 1 ND ND
Sample Deamidation Isomerization
Heavy Chain Heavy Chain
N52N53N54(G) N74(S) N84(S) Q112(G) N387(G)N392N393(Y) D62(S) D108(S)
“Unstressed” 1.3 ND ND ND 5.1 ND ND
“SEC monomers” 1.4 ND ND ND 5.5 ND ND
“SEC oligomers” 1.1 ND ND ND 5.7 ND ND
“SEC oligomers purified” 0.9 ND ND ND 4.9 ND ND
“SEC unfractionated” 1.0 ND ND ND 6.0 ND ND
“Supernatant” 1.1 ND ND ND 4.5 ND ND
“Pellet” 1.3 ND ND ND 4.8 ND ND
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control and “SECmonomers.” In sera of all positivemice, both IgG2a
and IgG2b, but no IgG3 or IgM ADA were found (Fig. 7b).
In experiment II, the immunogenicity of the most immunogenic
fraction, “Supernatant,” was investigated in a dose-response study.
As depicted in Figure 8a, the administered dose influenced the ADA
development in between studied groups (p ¼ 0.015). The lowest
dose induced ADA in the majority of mice, that is, 10 of 12. The
treatment with 10 and 30 mg of “Supernatant” triggered ADA in 5
and 2 mice per group, respectively. Moreover, the dose also influ-
enced activation of TFH cells in spleens and LNs on both early-stage
and late-stage of immunogenicity development. On day 10, so
before the development of ADA could be detected, the number of
TFH cells in spleens and LNs of mice administered with “Superna-
tant” seemed to be decreased when compared with “Unstressed”
control. However, the difference was statistically significant only
for the dose of 30 mg per injection (Supplementary Fig. S5). On day
65, the number of TFH cells in spleen was strongly influenced by
differences in treatment (Fig. 8b, p ¼ 0.0053). Injection of 3 and 10
mg of “Supernatant” led to increased numbers of TFH cells in spleens
when compared with “Unstressed” control. The number of TFH cells
in spleens of mice receiving 30 mg of “Supernatant” was similar to
that of the control. This trend was not observed in LNs, inwhich the
number of TFH cells was similar among all tested groups
(Supplementary Fig. S5).Discussion
Protein aggregates are considered one of the potential risk fac-
tors for immunogenicity. Several studies have correlated the pres-
ence of protein aggregates with increased rates of ADA
productions.11,13,15 However, despite years of studies, it is not fully
understood why mAb aggregates increase the risk of immunoge-
nicity and how aggregate features influence ADA formation. In this
study, we examined how the size of mAb aggregates influences the
immunogenicity upon SC administration in mice. To our best
knowledge this study was the first one in which the impact of
aggregate size on immunogenicity was comprehensively
investigated.Protein aggregates are heterogeneous in size and can vary from
small complexes of a few protein molecules up to visible particles.
The impact of protein aggregate size on immunogenicity is poorly
understood. Several reports tackling this problem have been
recently published.13-16,33 However, as the available data seems to
be conflicting, no universal conclusions can be drawn. In many
studies, multiple stress conditions were used to obtain aggregates.
In the study described by Filipe et al.,11 recombinant human IgG1
was stressed with 5 distinct stressors. The obtained formulations
were tested in immune tolerant mice for immunogenicity. Metal
oxidized recombinant human IgG was found to be the most
immunogenic even though this formulation contained the lowest
number of aggregates among the tested solutions. However, the
high number of variables between the formulations, such as
different levels of aggregation, aggregate size distribution, possible
chemical modifications, and conformational perturbations, makes
it is very difficult to identify the main cause of oxidized mAb's
immunogenicity. Another common limitation of experiments
described in the literature is immunogenicity evaluation of aggre-
gates of relatively similar size (e.g., dimers vs. small oligomers),
representing only a narrow range of aggregate sizes that might be
found in protein products.13 Therefore, on the basis of available
data, it is impossible to conclude whether a certain size of aggre-
gates is predominantly immunogenic or whether aggregate
characteristics other than size are more important.
To eliminate such confounding factors, aggregates tested in our
present study were prepared under almost identical stress condi-
tions. For centrifugation-based separation, the mIgG1 used in this
study was exposed to a combination of low pH, high temperature,
and stirring. Stirring stress has been included in the aggregation
protocol to ensure formation of micron size aggregates. However,
the presence of micron size particles in samples intended for SEC
separation was undesired. Thus, the mIgG1 intended for SEC
isolation of aggregates was exposed to low pH and elevated
temperature, but the stirring step used for centrifugation based
isolation was omitted. Despite the slight differences in aggregation
protocols, the obtained aggregates displayed very similar charac-
teristics apart from size. The SDS-PAGE electrophoresis revealed
that the aggregates present in isolated fractions were mostly non-
covalent assemblies. Fluorescence spectroscopy and CD analyses
Figure 7. (a) ADA in sera of mice injected with different mIgG1 fractions measured on day 65 (2 weeks post the last mIgG1 injection). (b) ADA isotypes measured in ADA positive
sera on day 65. Each dot represents the signal-to-background (S/B) ratio for an individual mouse. **p 0.01, ***p 0.001.
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when compared with “Unstressed” control. The analyses indicated
loss of b-sheet and exposure of hydrophobic sequences to the sol-
vent, but not complete denaturation. Importantly, no apparent
qualitative differences have been found among the different
aggregates. Liquid chromatography coupled with mass spectrom-
etry analysis confirmed that mIgG1 did not undergo any major
chemical modification during the aggregation procedure. More-
over, Western and dot blotting suggested that all aggregates still
contained epitopes found in “Unstressed” mIgG1. Taken together,
these results confirm that the major difference between the tested
fractions was the size of the mIgG1 aggregates.
The immunogenicity of isolated fractions was assessed in a
mouse model. Therefore “Unstressed” mIgG1 was expected to be
well tolerated and ADA to be triggered by aggregates. Indeed,
“Unstressed”mIgG1 did not trigger ADA in any of mice used in both
experiments. Centrifugation allowed separation of 2 fractions:
“Pellet,” enriched in micron size particles, and “Supernatant,”
mostly composed of submicron size particles and practically
micron particle free. Interestingly, in our mousemodel, particles >1Figure 8. (a) ADA in sera of mice injected with different doses of “Supernatant” fraction. Fo
number of positive mice per total number of mice. (b) Number of TFH (PD1þCXCR5þ) cells in
measurements were performed on day 65 (2 weeks post last mIgG1 injection). Each dot re
**p 0.01.mm in diameter seemed to be poorly immunogenic. This rather
unexpected result is in contrast to data reported by Freitag et al.15
and Telikepalli et al.,16 who found micron size aggregates to be
highly immunogenic. The use of a different protein and different
aggregation protocols might explain the differences between
studies. Moreover, in the study of Telikepalli et al. the immunoge-
nicity was assessed only in an in vitro assay, which might not
correlate with production of ADA (the main readout of our study).
In contrast to the “Pellet” fraction, the “Supernatant” fraction
induced ADA in most of the treated mice, indicating that in our
model, submicron size particles were significantly more immuno-
genic than micron size ones. The fractions isolated with SEC, that is,
“SEC Oligomers” and “SEC Oligomers Purified” were intended to
identify the submicron size particles size range responsible for the
ADA triggering. When particles bigger than ~100 nmwere removed
from “SEC Oligomers” by filtration and high speed centrifugation,
the immunogenic potential of the obtained formulation (“SEC
Oligomers purified”) was decreased: only one mouse in this group
was found to be ADA positive and the S/B ratio barely exceeded the
cutoff point. However, as SEC isolated fractions were poorlyr each group treated with aggregates, the number above the data points indicates the
spleens expressed as percentage of splenic T helper cell repertoire (CD3þCD4þ). Both
presents the result for an individual mouse. S/B: signal-to-background ratio. *p 0.05,
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this observation.
It was suggested that higher immunogenicity of protein aggre-
gates, when compared to monomeric protein, might be a result of
their prolonged retention at the SC injection site.34 Indeed, it has
been shown that aggregated proteins persist at the injection site
significantly longer than their monomeric counterparts.23,28,35 In
our previous study, we investigated the biodistribution of fluo-
rescently labeledmIgG1 aggregates upon SC injection inmice.23We
showed that submicron size particles were retained at the SC in-
jection site to a similar extent as micron size ones. Therefore, the
difference in immunogenicity of fractions enriched in micron size
particles and those containing mainly submicron size particles
suggest that retention at the injection site by itself is not sufficient
to trigger a strong ADA response. Therefore, the difference in
micron size and submicron size particles processing by antigen-
presenting cells most likely underlies the observed immunoge-
nicity profile in this case. Studies performed with polymeric
particles have shown that nanoparticles are taken up by dendritic
cells (DCs) more efficiently than microparticles.36-38 Although the
SC layer has no resident DCs, DCs from surrounding layers might
migrate into the SC injection site, where they encounter protein
aggregates.34 More efficient uptake and processing by DCs of sub-
micron size protein particles as compared to small oligomers (<100
nm) or micron size particles would explain the observed high
immunogenicity of the fraction enriched in submicron size partic-
ulates. However, as protein aggregates are structurally distinct from
polymeric particles, future studies are needed to confirm this hy-
pothesis. Moreover, the shape and rigidity of protein aggregates
may also affect their uptake efficiency and thereby their immuno-
genicity, as has been shown for particulate vaccine delivery sys-
tems.39 Another factor possibly contributing to the difference in
immunogenicity of submicron and micron size aggregates is
potentially different spacing of epitopes on these aggregates. It has
been shown that to efficiently crosslink B cell receptors and thereby
facilitate antibody responses, epitopes should form a
2-dimensional network with a spacing of about 5-10 nm between
the epitopes.40 As submicron size aggregates might be formed via a
different mechanism than micron size aggregates, it is possible that
the epitope density of on submicron aggregates of mIgG1 is more
favorable for triggering ADA. However, future studies are necessary
to confirm this hypothesis.
In experiment II, the influence of the administered dose of
“Supernatant,” the most immunogenic fraction in experiment I, on
its immunogenicity was investigated. Surprisingly, the dose
seemed to be negatively correlated with the ADA response and TFH
activation in spleens on day 65. This observation might be
explained as an effect of tolerogenic regulatory T helper cell epi-
topes (Tregitopes).41 We speculate that at lowmIgG1 dose, the load
of Tregitopes is not sufficient to effectively activate regulatory T
cells and thus inhibit ADA formation. However, higher load of
Tregitopes during injection of 10 mg and 30 mg of “Supernatant”
might overrule the immunogenic potential of increased submicron
particles dose, thereby downregulating a T celledependent
response. A relatively high dose of mIgG1 and consequent
immune system “overloading” by particles, might be another
explanation for the lower ADA production upon administration of
higher doses of “Supernatant.” A similar effect has been previously
described for IgG-coated glass particles.42 However, future exami-
nation is necessary to fully understand the exact mechanism
underlying the low immunogenicity of high doses of submicron
size particles.
Although the described results give valuable insight into the
impact of aggregate size on immunogenicity, it has to be noted that
a direct translation of our findings to humans is not possible.Despite fundamental similarities, the murine immune system dif-
fers from the human one and therefore the response observed in
mice might not fully reflect the type of response in human
patients.43 For instance, the Balb/c mouse model, although widely
used for in vivo studies, is inherently biased toward a Th2 type
immune response.44
Several published reports on immunogenicity of proteins lack
extensive characterization of aggregates, especially in the nano-
meter size range. In some studies the detection of nano size par-
ticles was not performed at all.15 Often these particles have been
detected only with DLS or similar techniques.14,45 However, one has
to be aware that when a heterogeneous aggregated protein solution
is measured, the accuracy of DLS measurements is low.46 According
to HP-SEC analysis, “SEC monomers” consisted of a similar amount
of monomeric IgG1 as “Unstressed” control. However, a small
amount of submicron size particles representing at most 4% of
protein in this formulation resulted in a significantly higher Zave,
that is, 120 nm versus 12 nm. Moreover, DLS does not provide
information on the quantity of particles in the solution. Our data
showing high immunogenicity of submicron size aggregates em-
phasizes the importance of detection and characterization of such
aggregates in protein formulations. It is especially important as
submicron size aggregates are often formed under a variety of
stress conditions.47-49Conclusion
In the presented study we tested the impact of mIgG1 aggre-
gates differing in size on their relative immunogenicity. Impor-
tantly, the applied stress conditions allowed generation of
differently sized aggregates with otherwise similar characteristics.
We found that the fraction enriched in submicron size particles
(0.1-1 mm) but not the fractions enriched in micron size aggregates
or soluble oligomers, were immunogenic in our model. In conclu-
sion, this study strongly indicates that aggregate size is an impor-
tant factor influencing immunogenicity of mAbs.Acknowledgments
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